Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 2150218, 13 pages
https://doi.org/10.1155/2018/2150218
Research Article

Resveratrol Prevents Diabetic Cardiomyopathy by Increasing Nrf2 Expression and Transcriptional Activity

Department of Cardiology, The Second Hospital of Jilin University, Jilin University, Changchun 100032, China

Correspondence should be addressed to Bing Liu; moc.anis.piv@3333nibuil

Received 16 August 2017; Revised 7 December 2017; Accepted 27 December 2017; Published 12 March 2018

Academic Editor: Yoshifumi Saisho

Copyright © 2018 Guan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Yilmaz, U. Canpolat, S. Aydogdu, and H. E. Abboud, “Diabetic cardiomyopathy; summary of 41 years,” Korean Circulation Journal, vol. 45, no. 4, pp. 266–272, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Yoshimura, R. Anzawa, and S. Mochizuki, “Cardiac metabolism in diabetes mellitus,” Current Pharmaceutical Design, vol. 14, no. 25, pp. 2521–2526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. O. Asghar, A. Al-Sunni, K. Khavandi et al., “Diabetic cardiomyopathy,” Clinical Science, vol. 116, no. 10, pp. 741–760, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Cohen-Solal, F. Beauvais, and D. Logeart, “Heart failure and diabetes mellitus: epidemiology and management of an alarming association,” Journal of Cardiac Failure, vol. 14, no. 7, pp. 615–625, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Khullar, A. A.-R. S. Al-Shudiefat, A. Ludke, G. Binepal, and P. K. Singal, “Oxidative stress: a key contributor to diabetic cardiomyopathy,” Canadian Journal of Physiology and Pharmacology, vol. 88, no. 3, pp. 233–240, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Giacco and M. Brownlee, “Oxidative stress and diabetic complications,” Circ Res, vol. 29, no. 107, pp. 1058–1070, 2010. View at Google Scholar
  7. H. Chen, X. Yang, K. Lu et al., “Inhibition of high glucose-induced inflammation and fibrosis by a novel curcumin derivative prevents renal and heart injury in diabetic mice,” Toxicology Letters, vol. 278, pp. 48–58, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Cai and Y. J. Kang, “Oxidative stress and diabetic cardiomyopathy: a brief review,” Cardiovascular Toxicology, vol. 1, no. 3, pp. 181–193, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Münzel, T. Gori, R. M. Bruno, and S. Taddei, “Is oxidative stress a therapeutic target in cardiovascular disease?” European Heart Journal, vol. 31, no. 22, pp. 2741–2748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. R. G. Baker, M. S. Hayden, and S. Ghosh, “NF-κB, inflammation, and metabolic disease,” Cell Metabolism, vol. 13, no. 1, pp. 11–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. G. P. Sykiotis, I. G. Habeos, A. V. Samuelson, and D. Bohmann, “The role of the antioxidant and longevity-promoting Nrf2 pathway in metabolic regulation,” Current Opinion in Clinical Nutrition & Metabolic Care, vol. 14, no. 1, pp. 41–48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. B. de Haan, “Nrf2 activators as attractive therapeutics for diabetic nephropathy,” Diabetes, vol. 60, no. 11, pp. 2683-2684, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. McMahon, K. Itoh, M. Yamamoto, and J. D. Hayes, “Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression,” The Journal of Biological Chemistry, vol. 278, no. 24, pp. 21592–21600, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. V. W. Dolinsky and J. R. B. Dyck, “Calorie restriction and resveratrol in cardiovascular health and disease,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1812, no. 11, pp. 1477–1489, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. A. A. Bertelli and D. K. Das, “Grapes, wines, resveratrol, and heart health,” Journal of Cardiovascular Pharmacology, vol. 54, no. 6, pp. 468–476, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. V. Penumathsa and N. Maulik, “Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease,” Canadian Journal of Physiology and Pharmacology, vol. 87, no. 4, pp. 275–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Das and D. K. Das, “Resveratrol: a therapeutic promise for cardiovascular diseases,” Recent Patents on Cardiovascular Drug Discovery, vol. 2, no. 2, pp. 133–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Gurusamy, I. Lekli, S. Mukherjee et al., “Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway,” Cardiovascular Research, vol. 86, no. 1, pp. 103–112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Cai, J. Wang, Y. Li et al., “Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy,” Diabetes, vol. 54, no. 6, pp. 1829–1837, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Zhou, X. Li, D. W. Hein et al., “Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart,” Journal of the American College of Cardiology, vol. 52, no. 8, pp. 655–666, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Yang, Y. Tan, F. Zhao et al., “Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage,” American Journal of Physiology-Endocrinology and Metabolism, vol. 301, no. 1, pp. E132–E144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Cheng, Z. Jin, R. Zhao, K. Ren, C. Deng, and S. Yu, “Resveratrol attenuates inflammation and oxidative stress induced by myocardial ischemia-reperfusion injury: role of Nrf2/ARE pathway,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 7, pp. 10420–10428, 2015. View at Google Scholar · View at Scopus
  24. H. Gencoglu, M. Tuzcu, A. Hayirli, and K. Sahin, “Protective effects of resveratrol against streptozotocin-induced diabetes in rats by modulation of visfatin/sirtuin-1 pathway and glucose transporters,” International Journal of Food Sciences and Nutrition, vol. 66, no. 3, pp. 314–320, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Wu, A. Huang, J. Yan et al., “Resveratrol Ameliorates Cardiac Dysfunction by Inhibiting Apoptosis via the PI3K/Akt/FoxO3a Pathway in a Rat Model of Diabetic Cardiomyopathy,” Journal of Cardiovascular Pharmacology, vol. 70, no. 3, pp. 184–193, 2017. View at Publisher · View at Google Scholar · View at Scopus
  26. H.-C. Su, L.-M. Hung, and J.-K. Chen, “Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats,” American Journal of Physiology-Renal Physiology, vol. 290, no. 6, pp. E1339–E1346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Palsamy and S. Subramanian, “Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1812, no. 7, pp. 719–731, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Zhu, C. Wu, S. Qiu, X. Yuan, and L. Li, “Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: Systematic review and meta-analysis,” Journal of Nutrition and Metabolism, vol. 14, no. 1, article no. 60, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Mohammadshahi, F. Haidari, and F. G. Soufi, “Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress,” Cardiology Journal, vol. 21, no. 1, pp. 39–46, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Wang, Q. Yang, Y. Y. Sun et al., “Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice,” Journal of Cellular and Molecular Medicine, vol. 18, no. 8, pp. 1599–1611, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. V. W. Dolinsky, S. Chakrabarti, T. J. Pereira et al., “Resveratrol preventshypertension and cardiac hypertrophy in hypertensive rats and mice,” Biochimica et Biophysica Acta, vol. 1832, no. 10, pp. 1723–1733, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. X. Li, Y. Dai, S. Yan et al., “Resveratrol lowers blood pressure in spontaneously hypertensive rats via calcium-dependent endothelial NO production,” Clinical and Experimental Hypertension, vol. 38, no. 3, pp. 287–293, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. A. A. Javkhedkar, Y. Quiroz, B. Rodriguez-Iturbe, N. D. Vaziri, M. F. Lokhandwala, and A. A. Banday, “Resveratrol restored Nrf2 function, reduced renal inflammation, and mitigated hypertension in spontaneously hypertensive rats,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 308, no. 10, pp. R840–R846, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Mozafari, A. A. Nekooeian, M. R. Panjeshahin, and H. R. Zare, “The effects of resveratrol in rats with simultaneous type 2 diabetes and renal hypertension: A study of antihypertensive mechanisms,” Iranian Journal of Medical Sciences, vol. 40, no. 2, pp. 152–160, 2015. View at Google Scholar · View at Scopus
  35. A. Ceriello, M. A. Ihnat, and J. E. Thorpe, “The “Metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications?” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 2, pp. 410–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Zhang, X. Lu, and Y. Tan, Diabete deficient mouse model. PLoS One, vol. 7, 2012.
  37. J. Chalmers and M. E. Cooper, “UKPDS and the legacy effect,” The New England Journal of Medicine, vol. 359, no. 15, pp. 1618–1620, 2008. View at Publisher · View at Google Scholar
  38. D. M. Nathan, P. A. Cleary, and J. Y. Backlund, “The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2643–2653, 2005. View at Publisher · View at Google Scholar
  39. G. Roman and N. Hancu, “Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.,” Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme, vol. 41, no. 2, pp. 116–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Nguyen, P. Nioi, and C. B. Pickett, “The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress,” The Journal of Biological Chemistry, vol. 284, no. 20, pp. 13291–13295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. X. He, H. Kan, L. Cai, and Q. Ma, “Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes,” Journal of Molecular and Cellular Cardiology, vol. 46, no. 1, pp. 47–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Tan, T. Ichikawa, J. Li et al., “Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo,” Diabetes, vol. 60, no. 2, pp. 625–633, 2011. View at Publisher · View at Google Scholar · View at Scopus